IP Library Granted Patent US 7,811,606
Granted Patent B2
US 7,811,606 · App. 10/414,756 · Granted Oct 12, 2010

Nasal pharmaceutical formulations and methods of using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,811,606
App. No.
10/414,756
Granted
Oct 12, 2010
Kind
B2
Abstract

Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific particle size distribution profile. In a preferred embodiment, the corticosteroid is beclomethasone or a pharmaceutically acceptable derivative thereof for the treatment of one or more symptoms of rhinitis. Preferably, the drug substance is beclomethasone dipropionate. The formulations herein may be provided as an aqueous suspension suitable for inhalation via the intranasal route.

Claims (33)

1. A nasal pharmaceutical formulation comprising an aqueous suspension of a therapeutically effective amount of a drug substance, wherein the therapeutically effective amount of a drug substance comprises about 0.01% to about 1% of beclomethasone, the aqueous suspension has the following suspended solid active drug substance particle size distribution profile:

(i) about 10% of the drug substance particles have a particle size of less than 0.3 microns;

(ii) about 25% of the drug substance particles have a particle size of less than 0.55 microns;

(iii) about 50% of the drug substance particles have a particle size of less than 1.1 microns;

(iv) about 75% of the drug substance particles have a particle size of less than 1.8 microns; and

(v) about 90% of the drug substance particles have a particle size of less than 2.7 microns;

wherein the formulation is suitable for administration to the nasal mucosa of an individual.

2. The formulation of claim 1 , wherein the nasal pharmaceutical formulation is sterile.

3. The formulation of claim 1 , wherein the nasal pharmaceutical formulation further comprises a preservative.

4. The formulation of claim 1 , wherein the nasal pharmaceutical formulation is stable.

5. The formulation of claim 1 , wherein the formulation is in a metered-dose spray pump bottle.

6. The formulation of claim 1 , wherein the nasal pharmaceutical formulation comprises about 0.04% to about 0.045% by weight of beclomethasone.

7. An aqueous nasal spray formulation comprising:

an aqueous suspension of about 0.04% to about 0.045% by weight beclomethasone; wherein the aqueous suspension has the following suspended solid beclomethasone particle size distribution profile:

(i) about 10% of the drug substance particles have a particle size of less than 0.30 microns;

(ii) about 25% of the drug substance particles have a particle size of less than 0.55 microns;

(iii) about 50% of the drug substance particles have a particle size of less than 1.10 microns;

(iv) about 75% of the drug substance particles have a particle size of less than 1.80 microns; and

(v) about 90% of the dmg substance particles have a particle size of less than 2.70 microns;

wherein the formulation is suitable for administration to the nasal mucosa of an individual.

8. The formulation of claim 7 , wherein the nasal pharmaceutical formulation further comprises a preservative.

9. The aqueous nasal spray formulation of claim 8 , wherein the nasal spray formulation is placed in a metered-dose, manual pump spray unit.

10. The aqueous nasal spray formulation of claim 8 , wherein the formulation comprises about 0.042% w/w beclomethasone disproportionate, calculated on a dried basis, in an aqueous medium.

11. The aqueous nasal spray formulation of claim 8 , wherein the formulation further comprises one or more of the following compounds:

(a) microcrystalline cellulose;

(b) carboxymethyl cellulose sodium;

(c) dextrose;

(d) benzalkonium chloride;

(e) polysarbate 80; and

(f) phenylethyl alcohol.

12. The formulation of claim 8 , wherein the nasal pharmaceutical formulation is sterile.

13. The formulation of claim 8 , wherein the nasal pharmaceutical formulation is stable.

14. The formulation of claim 8 , wherein the formulation is in a metered-dose spray pump bottle.

Assignments (7)
ADDRESS CHANGE Recorded Mar 15, 2022
From: MYLAN SPECIALTY L.P.
To: MYLAN SPECIALTY L.P.
Reel/Frame 059366/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2013
From: DEY PHARMA, L.P.
To: MYLAN SPECIALTY L.P.
Reel/Frame 030482/0242 →
PATENT RELEASE Recorded Dec 10, 2012
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: DEY PHARMA L.P. (F/K/A DEY, L.P.); MYLAN PHARMACEUTICALS, INC.; MYLAN BERTEK PHARMACEUTICALS INC.; MYLAN TECHNOLOGIES, INC.; SOMERSET PHARMACEUTICALS, INC.; MYLAN INSTITUTIONAL INC. (F/K/A UDL LABORATORIES, INC.); MYLAN INC.
Reel/Frame 029440/0967 →
CHANGE OF NAME Recorded Dec 8, 2011
From: DEY, L.P.
To: DEY PHARMA, L.P.
Reel/Frame 027351/0334 →
SECURITY AGREEMENT Recorded Nov 21, 2011
From: MYLAN PHARMACEUTICALS, INC.; MYLAN BERTEK PHARMACEUTICALS INC.; MYLAN TECHNOLOGIES, INC.; MYLAN INSTITUTIONAL INC. (F/K/A UDL LABORATORIES, INC.); SOMERSET PHARMACEUTICALS, INC.; DEY PHARMA, L.P. (F/K/A DEY L.P.)
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 027270/0799 →
RELEASE OF SECURITY INTEREST Recorded Nov 18, 2011
From: JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: MYLAN TECHNOLOGIES, INC.; DEY, INC. (F/K/A DEY LABORATORIES, INC.); MYLAN BERTEK PHARMACEUTICALS INC.; MYLAN PHARMACEUTICALS, INC.; DEY PHARMA, L.P. (F/K/A DEY L.P.); MYLAN INSTITUTION INC. (F/K/A UDL LABORATORIES, INC.); MYLAN INC. (F/K/A MYLAN LABORATORIES INC.)
Reel/Frame 027261/0928 →
SECURITY AGREEMENT Recorded Oct 24, 2007
From: MYLAN LABORATORIES INC.; DEY, L.P.; DEY, INC.; MYLAN PHARMACEUTICALS, INC.; MYLAN TECHNOLOGIES, INC.; MYLAN BERTEK PHARMACEUTICALS INC.; UDL LABORATORIES, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 020004/0404 →